Replies to post #305674 on Option Millionaires

[jimmybob]

If it shows the same or better then their phase 2 data its $115+... if inline or worse then maybe $80.. a miss and its $10 or so

Down the line OPHT can have a somewhat similar run to REGN though they do not have nearly as much in their pipeline

REGN maybe a good play for downside as well.. if OPHT data hits on all cylinders REGN will likely be looked at as a losing quite a bit of business down the road

But in the grand scheme, the market for Age-related macular degeneration is still growing at a fast rate